As we approach the end of 2024, the HARMONY Alliance reflects with immense pride on a year marked by groundbreaking achievements and continued dedication to advancing healthcare and improving outcomes for patients with hematologic malignancies. This year has been transformative for our community, and it is with gratitude and excitement that we share some of our most significant milestones.
One of our crowning achievements in 2024 was the establishment of the HARMONY Alliance Foundation. This vital initiative represents a significant step forward in ensuring the sustainability and expansion of our mission. The Foundation will serve as a cornerstone for our efforts to unite stakeholders across academia, industry, healthcare, and patient advocacy groups. Its creation underscores our commitment to fostering collaboration and innovation while providing a robust platform to address emerging challenges and opportunities in hematologic research and treatment.
Another standout accomplishment this year was the publication of five research articles in high-impact scientific journals. These publications represent the collective expertise and tireless work of our consortium members, showcasing innovative methodologies and critical findings that address some of the most pressing challenges in hematologic malignancies. From improving diagnostic precision to advancing personalized treatment approaches, these studies contribute valuable knowledge to the global scientific community and further cement the HARMONY Alliance’s reputation as a leader in hematology research.
Finally, in what we see as a major recognition of our capabilities and contributions, the HARMONY Alliance was officially accepted as a DARWIN EU® Network Data Partner. This prestigious designation aligns us with the European Medicines Agency’s vision for advancing real-world evidence and data-driven healthcare solutions. Our inclusion in this network amplifies our capacity to deliver insights that shape regulatory decisions, enhance therapeutic strategies, and ultimately improve patient care. It is a testament to the quality and impact of our data-driven research efforts, as well as the trust placed in our Alliance by the academic and regulatory communities.
These achievements are the result of the dedication and collaboration of all our partners. The HARMONY Alliance is powered by a diverse network of experts and organizations, and it is this collective effort that drives our joint success. We extend our heartfelt thanks to every member of our community for their unwavering support, innovative contributions, and shared vision for a healthier future.
As we look to 2025, we remain steadfast in our mission to harness big data and advanced analytics to accelerate research, improve clinical practice, and transform patient outcomes. The road ahead is filled with promise, and we are excited to build upon this year’s successes to achieve even greater impact in the years to come.
To our partners, collaborators, and supporters, thank you for your continued trust and engagement. Together, we are making significant strides toward a brighter future for patients and their families. Here’s to a 2025 of progress, innovation, and HARMONY.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
